**Supplemental Digital Content 2.** Highest level of respiratory support, by demographic characteristic and co-infection status.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Characteristic** | **None or low-flow oxygen, only** | **HFNC** | **Noninvasive ventilation (BiPAP/CPAP)** | **Invasive mechanical ventilation** |
| **All patients** | 369 | 130 | 47 | 51 |
| **Age group** |  |  |  |  |
| 8 months to <2 years | 220 (59.6) | 91 (70.0) | 27 (57.4) | 33 (64.7) |
| 2 years to <5 years | 149 (40.4) | 39 (30.0) | 20 (42.6) | 18 (35.3) |
| **Sex** |  |  |  |  |
| Male | 212 (57.5) | 77 (59.2) | 22 (46.8) | 27 (52.9) |
| Female | 157 (42.5) | 53 (40.8) | 25 (53.2) | 24 (47.1) |
| **Race/ethnicity** |  |  |  |  |
| White, Nnon-Hispanic | 159 (43.1) | 42 (32.3) | 13 (27.7) | 25 (49.0) |
| Black, Non-Hispanic | 70 (19.0) | 25 (19.2) | 6 (12.8) | 11 (21.6) |
| Asian, Non-Hispanic | 19 (5.1) | 7 (5.4) | 2 (4.3) | 4 (7.8) |
| Hispanic/Latino | 86 (23.3) | 39 (30.0) | 19 (40.4) | 6 (11.8) |
| Multiple/Other, Non-Hispanic | 22 (6.0) | 13 (10.0) | 4 (8.5) | 3 (5.9) |
| Unknown | 13 (3.5) | 4 (3.1) | 3 (6.4) | 2 (3.9) |
| **Census region** |  |  |  |  |
| Northeast | 60 (16.3) | 15 (11.5) | 7 (14.9) | 8 (15.7) |
| Midwest | 81 (22.0) | 32 (24.6) | 7 (14.9) | 13 (25.5) |
| South | 134 (36.3) | 47 (36.2) | 8 (17.0) | 16 (31.4) |
| West | 94 (25.5) | 36 (27.7) | 25 (53.2) | 14 (27.5) |
| **Underlying medical conditions** |  |  |  |  |
| None | 174 (47.2) | 60 (46.2) | 21 (44.7) | 18 (35.3) |
| One or more underlying medical condition | 195 (52.8) | 70 (53.8) | 26 (55.3) | 33 (64.7) |
| Multiple underlying medical conditions | 60 (16.3) | 19 (14.6) | 15 (31.9) | 18 (35.3) |
| Cardiorespiratory | 109 (29.5) | 49 (37.7) | 21 (44.7) | 25 (49.0) |
| Respiratory | 77 (20.9) | 42 (32.3) | 17 (36.2) | 23 (45.1) |
| Asthma | 26 (7.0) | 13 (10.0) | 5 (10.6) | 3 (5.9) |
| Cardiac | 48 (13.0) | 14 (10.8) | 5 (10.6) | 10 (19.6) |
| Non-cardiac/Non-respiratory | 86 (23.3) | 21 (16.2) | 5 (10.6) | 8 (15.7) |
| Oncologic or immunosuppressed | 33 (8.9) | 3 (2.3) | 0 | 1 (2.0) |
| * Non-oncologic immunosuppressive disorder | 13 (3.5) | 3 (2.3) | 0 | 0 |
| * Oncologic | 20 (5.4) | 0 | 0 | 1 (2.0) |
| Neurologic/neuromuscular | 64 (17.3) | 24 (18.5) | 14 (29.8) | 18 (35.3) |
| Endocrine | 20 (5.4) | 4 (3.1) | 3 (6.4) | 4 (7.8) |
| **Viral co-detection**a |  |  |  |  |
| Any viral co-detection | 83/304 (27.3) | 59/109 (54.1) | 28/43 (65.1) | 18/43 (41.9) |
| Multiple co-detections | 8/304 (2.6) | 12/109 (11.0) | 4/43 (9.3) | 2/43 (4.7) |
| Influenza | 3/304 (1.0) | 2/109 (1.8) | 1/43 (2.3) | 0/43 (0) |
| RSV | 22/298 (7.4) | 21/106 (19.8) | 8/43 (18.6) | 5/43 (11.6) |
| Other respiratory viral co-detectionsb | 60/191 (31.4) | 41/87 (47.1) | 23/36 (63.9) | 13/39 (33.3) |

a We collected information regarding testing for the following non-SARS-CoV-2 respiratory viruses: influenza, RSV, parainfluenza (types 1, 2, 3, and 4), human metapneumovirus, adenovirus, or rhinovirus/enterovirus. All 499 patients were tested for influenza

b Other viral co-detections include any child who tested positive for parainfluenza (types 1, 2, 3, and 4), human metapneumovirus, adenovirus, or rhinovirus/enterovirus.